Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 218 5.7 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197 5.2 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 258 6.8 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 6.1 20 to 24 years . . . . . . . . . . . . . . . . . . . . ....

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176 6.2 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 5.7 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173 6.1 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 5.6 20 to 24 years . . . . . . . . . . . . . . . . . . . . ....

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 202 5.9 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216 6.3 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 7.7 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 266 7.7 20 to 24 years . . . . . . . . . . . . . . . . . . . . ....

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 332 5.5 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 369 6.1 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 471 7.8 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423 7.0 20 to 24 years . . . . . . . . . . . . . . . . . . . . ....

A bacteriocin produced by Bacillus megaterium ATCC 19213 was identified, purified, and compared with megacin A from B. megaterium 216. The ATCC 19213 bacteriocin was inducible with mitomycin C and showed phospholipase A activity. Both megacin A-216 and megacin A-19213 contained two dissimilar polypeptide subunits. Megacin A-216 contains a 30,000-dalton alpha subunit and a 15,000-dalton beta sub...

AIMS Apolipoprotein A-1 (ApoA-1), based on epidemiology, is inversely associated with cardiovascular (CV) events. Human carriers of the ApoA-1 Milano variant have a reduced incidence of CV disease. Regression of atherosclerotic plaque burden was previously observed on intravascular ultrasound (IVUS) with ETC-216, a predecessor of MDCO-216. MDCO-216, a complex of dimeric ApoA-1 Milano and 1-palm...

PURPOSE Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) signaling in the acquired lapatinib resistance in HER2-positive GC cells. MATERIALS AND METHODS La...

a NASA Goddard Space Flight Center, Code 699, Greenbelt, MD 20771 5 b Department of Chemistry and Biochemistry and Cooperative Institute for Research in Environmental Sciences, University of Colorado at Boulder, UCB 216, Boulder, CO 80309 c Division of Geological and Planetary Sciences, California Institute of Technology, Pasadena, CA 91125 d Laboratory for Atmospheric and Space Physics and Dep...

4 Dobromir Rahnev, Peter Kok, Moniek Munneke, Linda Bahdo, Floris P. de Lange, 5 Hakwan Lau 6 7 1 Columbia University, Department of Psychology, New York, USA 8 2 Radboud University Nijmegen, Donders Institute for Brain, Cognition and Behavior, 9 Netherlands 10 11 12 Abbreviated title: Theta burst TMS reduces resting state connectivity 13 14 Manuscript information: This manuscript contains 216 ...

∗ Corresponding author: Dr. Mahfuzur Sarker, Department of Biomedical Sciences, College of 18 Veterinary Medicine, Oregon State University, 216 Dryden Hall, Corvallis, OR 97331. Tel: 54119 737-6918; Fax: 541-737-2730; e-mail: [email protected] 20 Copyright © 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Appl. Environ. Microbiol. doi:1...